SCHEMBL377757

SCHEMBL377757

COC(=O)c1ccc2[nH]nc(COC3CCCCO3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 4/20 0.40
MAPK1 P28482 1/20 0.40
FGFR1 P11362 1/20 0.40
FLT1 P17948 1/20 0.40
CREBBP Q92793 2/20 0.38
ULK1 O75385 1/20 0.38
EP300 Q09472 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
PARP1 P09874 1/20 0.37
MAPKAPK2 P49137 1/20 0.37
CHEK1 O14757 1/20 0.37
CDK7 P50613 1/20 0.37
NQO2 P16083 1/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
HPGD P15428 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL616627 0.80 ICAM1 (0.38) MEN1KMT2AALDH1A1MAPK1CREBBP
SCHEMBL378275 0.79 KDM4C (0.36) MEN1KMT2ACREBBPEP300NPC1
SCHEMBL22527956 0.79 KMT2A (0.44) MEN1KMT2AALDH1A1MAPK1FGFR1
SCHEMBL29392240 0.79 KMT2A (0.44) MEN1KMT2AALDH1A1MAPK1FGFR1
SCHEMBL23535719 0.78 MEN1 (0.41) MEN1KMT2AALDH1A1MAPK1CREBBP
SCHEMBL30159612 0.78 MEN1 (0.41) MEN1KMT2AALDH1A1MAPK1CREBBP
SCHEMBL31504550 0.78 MEN1 (0.41) MEN1KMT2AALDH1A1MAPK1CREBBP
SCHEMBL30514529 0.78 ALDH1A1 (0.41) MEN1KMT2AALDH1A1MAPK1CREBBP
SCHEMBL24570312 0.78 ALDH1A1 (0.41) MEN1KMT2AALDH1A1MAPK1CREBBP
SCHEMBL3809200 0.76 KMT2A (0.48) MEN1KMT2AALDH1A1MAPK1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 EP disclosed
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 US disclosed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 US disclosed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 US disclosed
US-9238640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2016-01-19 US disclosed
WO-2013175281-A1 USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS RVX THERAPEUTICS INC. (CA) 2013-11-28 WO disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 US disclosed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 EP disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 MEN1 3826/4885KMT2A 4037/4885ALDH1A1 587/4885
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 MEN1 3913/4885KMT2A 3826/4885ALDH1A1 650/4885
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 MEN1 4236/4885KMT2A 199/4885ALDH1A1 3920/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 MEN1 3826/4885KMT2A 4037/4885ALDH1A1 587/4885
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 MEN1 3826/4885KMT2A 4037/4885ALDH1A1 587/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 MEN1 3826/4885KMT2A 4037/4885ALDH1A1 587/4885
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 MEN1 3913/4885KMT2A 3826/4885ALDH1A1 650/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 MEN1 3913/4885KMT2A 3826/4885ALDH1A1 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.